Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca commences phase III study of new asthma therapy

AstraZeneca commences phase III study of new asthma therapy

30th October 2013

AstraZeneca has announced the start of a phase III clinical trial programme for a potential treatment for severe uncontrolled asthma.

The compound benralizumab is a monoclonal antibody developed by AstraZeneca's global biologics research and development arm MedImmune and has already demonstrated promise in phase II studies.

Dubbed Windward, the new phase III programme will commence with a study called Calima, which will assess whether the drug can reduce the number of exacerbations in severe asthma patients who remain uncontrolled despite treatment with inhaled corticosteroids in combination with a second controller, such as a long-acting beta agonist.

The Windward programme will also include two pivotal exacerbation trials, an oral corticosteroid-reducing trial and a long-term safety study.

William Mezzanotte, vice-president and head of respiratory, inflammation and neuroscience at AstraZeneca's global medicines development unit, said: "Benralizumab has the potential to address an important area of unmet medical need as there are currently limited treatment options available for patients with severe uncontrolled asthma."

This comes after AstraZeneca confirmed earlier this month that MedImmune has entered into a deal to acquire the privately-held biotechnology company Spirogen.ADNFCR-8000103-ID-801654997-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.